There are no controlled trials of microinfusion-delivered peptides and growth factors in pregnancy, and the regulatory and clinical default in the absence of safety data is non-intervention
If you have any of these symptoms, especially if you have more than one, you should take them seriously
Clinical studies have used schedules more intensive than those seen in recovery practice: patients with Parkinson's disease received 1,400 mg three times a week for four weeks (Hauser et al., Movement Disorders 2009, PMID 19230029), while studies on skin lightening used 1,200 mg twice a week for six weeks (Alzahrani et al., Cureus 2025, PMID 40013212)
Excessively rapid loss may indicate intolerance or underlying complications
Frequently asked questions about semaglutide plateaus Hitting a plateau can feel frustrating and confusing, especially when youve been making progress
calculated the risk to be 4.8/10,000 in groups taking GLP-1 RAs compared to 4.6/10,000 in the control groups, failing to show a statistically significant difference in aspiration or other complications between the two groups (Chang et al